NEOsphere Biotechnologies GmbH

Henrik is a pioneer and scientific leader in the field of proteomics-based drug discovery with over 20 years of industry experience commercializing cutting-edge proteomics technologies. Tanja is a business economist and expert in strategic and analytical business management. Martin has pioneered various state-of-the-art proteomics methods to validate target candidates of protein degraders. Uli is a leading expert in industrial-scale, deep proteomic screening. Björn is a trained mathematician with a PhD in computational biology from the Ludwig-Maximilians-University in Munich and a degree in machine learning from Stanford University. Andreas is a serial entrepreneur with more than 20 years of leadership experience in the life sciences industry. Vadim is a research group leader at the Charité – Universitätsmedizin Berlin, focusing on developing innovative mass spectrometry methods and data analysis approaches for proteomics. NEOsphere Biotechnologies is a pioneering proteomics company that creates value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets not yet exploited.